Title:
6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/103070
Kind Code:
A1
Abstract:
Provided are: a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. (In the formula, R1 and R2 independently represent a hydrogen atom, a C1−4 alkyl or the like; ring A represents a C6−10 aromatic carbon ring group, a 4 to 10 membered saturated heterocyclic group or the like; R3 and R4 independently represent a hydrogen atom, a halogen atom, a C1−6 alkyl, a C1−4 alkoxy or the like; R5 and R6 independently represent a hydrogen atom, a C1−6 alkyl, a C1−6 alkoxy, an −NRaRb or the like; Ra and Rb independently represent a hydrogen atom, a C1−4 alkyl or the like; X represents a nitrogen atom or a −CRe−; and Re represents a hydrogen atom, a halogen atom, a C1−6 alkyl or the like).
More Like This:
Inventors:
IKUMA YOHEI (JP)
Application Number:
PCT/JP2018/043094
Publication Date:
May 31, 2019
Filing Date:
November 22, 2018
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
International Classes:
A61K31/4985; C07D519/00; A61K45/00; A61P3/04; A61P25/00; A61P25/04; A61P25/08; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P43/00
Domestic Patent References:
| WO2014195311A1 | 2014-12-11 | |||
| WO2016087487A1 | 2016-06-09 | |||
| WO2016016382A1 | 2016-02-04 | |||
| WO2017018475A1 | 2017-02-02 | |||
| WO2009062676A2 | 2009-05-22 | |||
| WO2010060589A1 | 2010-06-03 | |||
| WO2014195311A1 | 2014-12-11 | |||
| WO2016016380A1 | 2016-02-04 | |||
| WO2016016381A1 | 2016-02-04 | |||
| WO2016016382A1 | 2016-02-04 | |||
| WO2016016383A1 | 2016-02-04 | |||
| WO2016016395A1 | 2016-02-04 | |||
| WO2016087487A1 | 2016-06-09 |
Other References:
HEMSTAPAT ET AL., PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 322, 2007, pages 254 - 264
LUNGSTROM ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 164, 2011, pages 521 - 537
DORE ET AL., NATURE, vol. 511, 2014, pages 557 - 562
CHAKI ET AL., NEUROPHARMACOLOGY, vol. 66, 2013, pages 40 - 52
HIGGINS ET AL., NEUROPHARMACOLOGY, vol. 46, 2004, pages 907 - 917
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS, INC.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 63, 2015, pages 6 - 13
CURR OPIN DRUG DISCOV DEVEL., vol. 13, no. 1, January 2010 (2010-01-01), pages 66 - 77
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 1, no. 1, 2005, pages 3 - 13
XENOBIOTICA, vol. 39, no. 2, 2009, pages 99 - 112
DRUG METABOLISM AND DISPOSITION, vol. 39, no. 7, 2011, pages 1247 - 1254
LUNGSTROM ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 164, 2011, pages 521 - 537
DORE ET AL., NATURE, vol. 511, 2014, pages 557 - 562
CHAKI ET AL., NEUROPHARMACOLOGY, vol. 66, 2013, pages 40 - 52
HIGGINS ET AL., NEUROPHARMACOLOGY, vol. 46, 2004, pages 907 - 917
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY AND SONS, INC.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 63, 2015, pages 6 - 13
CURR OPIN DRUG DISCOV DEVEL., vol. 13, no. 1, January 2010 (2010-01-01), pages 66 - 77
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, vol. 1, no. 1, 2005, pages 3 - 13
XENOBIOTICA, vol. 39, no. 2, 2009, pages 99 - 112
DRUG METABOLISM AND DISPOSITION, vol. 39, no. 7, 2011, pages 1247 - 1254
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF: